The benefits and risks of offlabel use of recombinant factor VIIa in patients without hemophilia are contested. We performed a systematic review to assess the effectiveness and safety of such use.
Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis
Yulia Lin MD, Simon Stanworth DPhil, Janet Birchall MB ChB, Carolyn Doree PhD, Christopher Hyde MBBS R ecombinant factor VIIa is a hemostatic agent licensed for the treatment of bleeding in patients with hemophilia who have inhibitors. It is also used off-label for the prevention and treatment of bleeding in patients without hemophilia.
In the Australian and New Zealand Haemostasis Registry, use of recombinant factor VIIa increased to a plateau in 2006, which was maintained through 2008. 1 Because only 1% of the 2700 patients in this registry had a diagnosis of hemophilia, physicians may believe that off-label use of this agent is effective and outweighs the risks. Randomized controlled trials (RCTs) evaluating recombinant factor VIIa have raised concerns about adverse effects, particularly thromboembolic events. 2−7 These concerns have been supported by passive surveillance reports from the US Food and Drug Administration's Adverse Event Reporting System, which suggest an increased risk among unselected patients. 8 In addition, although cost is but one component, at a dose of 80 µg/kg for a 70-kg patient, the approximate cost of 5.6 mg of recombinant factor VIIa would be $6270 in Canada (Chantal Couture, Canadian Blood Services, Ottawa, Ont.: personal communication, 2010) and £2800 in the United Kingdom. By contrast, the current cost of one unit of red blood cells is $419 in Canada (Marcel Leclair, Finance, Canadian Blood Services, Ottawa, Ont.: personal communication, 2010) and £133 in the United Kingdom (Julie Staves, National Health Service Blood and Transplant, Hertfordshire, UK: personal communication, 2010).
We conducted a systematic review and metaanalysis of the effectiveness and risks of recombinant factor VIIa in patients without hemophilia and assessed the implications of these results for future research.
2009), CINAHL, the UK Blood Transfusion and Tissue Transplantation Services Transfusion Evidence Library, LILACS, KoreaMed, IndMed, PakMediNet, mRCT, ClinicalTrials.gov and the World Health Organization's ICTRP Database (Appendix 1, available at www.cmaj.ca /cgi /content /full /cmaj .100408 /DC1). The search was not restricted by language, but we included only published, full-text versions of RCTs. We also checked the reference lists of the identified RCTs and recently published systematic reviews.
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Study selection
We included RCTs comparing recombinant factor VIIa with no treatment, an alternative treatment or different doses of recombinant factor VIIa in patients without hemophilia. We ex cluded RCTs involving patients with congenital bleeding disorders or healthy volunteers. Two of us (Y.L. and S.S.) independently screened all of the citations, including the titles and abstracts, and reviewed the full text of citations considered relevant.
Outcomes
We divided the RCTs into two groups: prophylactic use and therapeutic use. In the prophylactic group, recombinant factor VIIa was given to prevent anticipated bleeding, for example during an operation; in the therapeutic group, the agent was given to treat bleeding that was al ready established. For the studies of prophylactic use, the outcomes included mortality, total blood loss, use of red blood cell transfusion (measured in millilitres), number of patients re ceiving transfusions and number of thrombo embolic events. Thromboembolic events in cluded any reported arterial event (increased troponin level, myocardial infarction or ische mia, stroke and "other") or venous event (deep vein thrombosis, pulmonary embolus, thrombo phlebitis and "other"). For studies of therapeutic use, the same outcomes were used, except control of bleeding was measured instead of total blood loss.
Details on risk of bias (random sequence generation, concealment of allocation, blinding, loss to follow-up and power calculation) were collected. Two of us (Y.L., S.S. or J.B.) independently extracted data using a predesigned form; disagreements were resolved by consensus.
Statistical analysis
The meta-analysis was conducted using the random-effects model, decided a priori, because of the marked clinical heterogeneity. We performed a subgroup analysis in which low-dose therapy was defined as less than 80 µg/kg and standard or high-dose therapy was defined as 80 µg/kg or more. Because there was minimal difference in results between these groups, we present only combined results.
Data were combined using the MantelHaenszel method for dichotomous outcomes and inverse variance for continuous outcomes. Pooled estimates were reported as relative risks (RRs) for dichotomous data (e.g., mortality) and weighted mean differences for continuous data (e.g., transfusion requirements). A unit of red blood cells was assumed to be 300 mL. Statistical heterogeneity was examined using the I 2 statistic and visual inspection of graphs. Heterogeneity was explored post hoc using study size (< 50 v. ≥ 50 patients), concealment of allocation (adequate v. unclear or inadequate) and transfusion protocol (present v. absent).
Results
We identified 449 records through the literature search, from which 26 RCTs were included in the final analysis ( Figure 1) . The report by Boffard and coauthors was considered as two separate trials in blunt and penetrating trauma.
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Study and patient characteristics
Of the 26 RCTs, 14 were of the prophylactic use of recombinant factor VIIa, with study samples of 18 to 235 patients (Table 1) . (Tables 1-4 can be found at the end of the article.) The clinical settings included cardiopulmonary bypass surgery, 15−18 liver biopsy, 19 hepatic resection, 20, 21 liver transplantation, 22 −24 traumatic pelvic fracture, 25 spinal surgery, 26 radical prostatectomy 27 and skin excision following burns. 28 Dosing regimens varied from a single dose of 5 µg/kg to multiple doses totalling 360 µg/kg. 22, 26 The primary outcomes were predominantly blood loss, 25−27 red blood cell transfusion 16, [21] [22] [23] 27, 28 and number of patients receiving allogeneic transfusion. 15, 20, 21 Protocols for transfusion were reported in 8 of 11 RCTs. The main criterion for excluding patients was prior thromboembolic or vascular disease. Active surveillance for adverse events occurred in five studies. [20] [21] [22] [23] 27 Twelve RCTs were of the therapeutic use of recombinant factor VIIa, with sample sizes ranging from 28 to 400 patients ( Table 2 ). The clinical settings included trauma, 14 cirrhosis with upper gastrointestinal bleeding, 29, 30 bleeding after cardiac surgery, 31 dengue hemorrhagic fever, 32 bleeding after hemato poietic stem-cell transplant, 33 spontaneous intracranial hemorrhage 3,34−36 and traumatic intracranial hemorrhage. 37 Dosing regimens varied from a single dose of 5 µg/kg 36 to multiple doses totalling 1120 µg/kg. 33 The primary outcomes included control of bleeding, 29, 30, 32, 33, 35 transfusion requirements, 14 adverse events 31, 34, 36, 37 and, in one study of intracranial hemorrhage, a clinical com-bined outcome of severe disability or death. 3 Common exclusion criteria were history of clotting and hemorrhagic dia thesis. Transfusion protocols were not re quired in the studies of intracranial hemorrhage and were described in four of the remaining seven studies; specifically, they were not de scribed in the two trauma studies in which the primary outcome was transfusion requirement. 14 
Study quality
Overall, most of the 26 RCTs had some potential threats to validity (Table 3) , primarily because of the lack of detail provided in the report. Se quence generation was adequate in 13 trials, allocation concealment was adequate in 7, and blinding was adequate in 16 studies. A power calculation was performed and the target sample size was achieved in only 10 studies. Most of the studies (8 of the 14 prophylactic trials and all 12 of the therapeutic studies) were either supported by NovoNordisk (the manufacturer of recombinant factor VIIa) or were coauthored by an employee of NovoNordisk.
Outcomes
Prophylactic use
The pooled RR for mortality was 0.82 (95% confidence interval [CI] 0.36 to 1.83; I 2 = 0%). The individual results from the 13 studies that provided mortality data had a 95% CI that included 1.0 ( Figure 2 ). Rates of death in the placebo groups were generally low across all studies, the maximum being 3/9.
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Eight studies contributed data on blood loss. The pooled weighted mean difference was −276 mL (276 mL less blood loss in the recombinant factor VIIa arms; 95% CI −411 to −141 mL) ( Table 4 ). This finding is likely to be an overestimate of the effect of recombinant factor VIIa, since four studies reporting no difference could not be incorporated into the pooled analysis because outcomes were not available as means and standard deviations. 16, 21, 23, 25 Also, there was important statistical heterogeneity (I 2 = 78%); when we excluded studies with fewer than 50 patients, the I 2 value was 0%. Ten studies provided data on the use of red blood cell transfusion. The pooled weighted mean difference between the treatment and control arms was −281 mL (95% CI −433 to −129 mL) ( Table 4 ). This finding is again likely to be an overestimate of the effect of recombinant factor VIIa since three studies reporting no difference could not be incorporated into the pooled analysis because outcomes were not available as means and standard deviations. 16, 21, 25 There was evidence of significant heterogeneity (I 2 = 63%); when we excluded studies with fewer than 50 patients, the I 2 value was 0%. Seven studies reported and contributed data on the number of patients who received transfusions. The pooled RR was 0.71 (95% CI 0.50 to 0.99), with marked heterogeneity (I 2 = 61%) ( Table 4) . The proportion of patients who received transfusions in the control arms ranged from 37% 20 to 100%. 22 Twelve studies contributed data on thromboembolic events. The pooled RR was 1.38 (95% CI 0.76 to 2.51; I 2 = 0%). The 95% CIs in the individual studies all included 1.0 (Figure 3) . Rates of thromboembolic events in the control groups were generally low across the studies, the maximum being 2/10. 15 Therapeutic use All 12 studies contributed data on mortality. The pooled RR for overall mortality was 0.90 (95% CI 0.76 to 1.06), with no statistical heterogeneity (I 2 = 0%) ( Figure 2 ). All but one of the studies (the initial efficacy trial in spontaneous intracranial hemorrhage) yielded an RR with a 95% CI that included 1.0. 35 The rates of death in the control groups varied from 0/9 32 to 22/74 (30%). Research the pooled analysis. 29, 30, 32, 33 The pooled RR was 1.05 (95% CI 0.97 to 1.14; I 2 = 0%) ( Table 4 ). The five remaining trials were of therapeutic use of recombinant factor VIIa in intracranial hemorrhage; they measured control of bleeding in terms of hematoma growth, which could not be combined quantitatively.
3,34−37 None of the safety trials 34, 36, 37 showed a significant reduction in their secondary outcomes of growth of volume of hemorrhage. The initial efficacy study reported a statistically significant reduction in the growth of hemorrhage volume with recombinant factor VIIa associated with reduced disability at 90 days; 35 however, the second, larger, efficacy trial 3 found no significant difference between study groups in the primary outcome at 90 days. Only four studies contributed data on the use of red blood cell transfusion. 29−32 The pooled weighted mean difference was 21 mL (95% CI −108 to 150; I 2 = 0%) ( 
Research
E12
each of the four studies included zero (no difference). Because data from the RCT by Boffard and colleagues 14 were reported as medians and ranges, we could not incorporate them into the pooled analysis. The exclusion of these studies likely did not change the pooled weighted mean difference, because there was no significant difference in the primary outcome of number of units of red blood cells transfused for all patients at 48 hours.
Two of the 12 studies contributed data on the number of patients who received transfusions. 31, 32 The pooled RR was 0.81 (95% CI 0.70 to 0.93; I 2 = 0%) ( Table 4 ). For the trial of therapeutic use in the setting of cardiac surgery, 31 we used the number of patients who received transfusions within five days; this outcome favoured recombinant factor VIIa, as compared with the cut-off of 24 hours, which did not show a statistically significant difference between the study groups.
All of the trials of therapeutic use contributed data on thrombo embolic events. The pooled RR was 1.18 (95% CI 0.86 to 1.62; I 2 = 0%) ( Figure  3) . The 95% CIs of the individual studies all included 1.0. Rates of thromboembolic events in the control groups were generally low across all studies, the maximum being 3/8. 
Therapeutic use
Interpretation
We included 14 RCTs on the prophylactic use (n = 1137) and 12 on the therapeutic use (n = 2538) of recombinant factor VIIa in patients without hemophilia in our review. This number of trials might be considered to be sufficient for an informative result. However, the results indicated continuing uncertainty about the magnitude of benefits and harms. In the prophylactic studies, only modest benefits favouring recombinant factor VIIa were seen in the outcomes of blood loss, requirements of red blood cell transfusion (equivalent to less than one unit of red blood cells saved) and number of patients receiving transfusions. In the therapeutic studies, there was no clear advantage of recombinant factor VIIa over placebo for the outcomes of mortality, control of bleeding and transfusion requirements. However, for mortality, the 95% CI was close to significance and may be considered clinically important (RR 0.90; 95% CI 0.76 to 1.06). In both groups of trials, there was a trend toward increased thromboembolic events, al though most RCTs excluded patients with a history of thromboembolic events. Promising results in earlier therapeutic studies were not replicated in larger trials, 3, 30, 38 and the risk of bias assessment highlighted frequent problems in randomization, blinding and sample size.
Continued lack of clarity about the overall clinical effectiveness certainly stems from recombinant factor VIIa being genuinely less effective than was originally predicted. The trials in our review were undertaken across diverse clinical settings where different complex hemostatic pathways operate, and the expectation that recombinant factor VIIa would reverse all coagulopathy is inappropriate. 12 The findings of our review are similar to those of a recent appraisal by Hsia and colleagues. 4 However, we grouped the RCTs by how recombinant factor VIIa was used (prophylactic or therapeutic), because the expectations of benefit and acceptance of risk in these two situations are different. This separation and greater attention to the risk of bias in the included stud ies has emphasized the degree of uncertainty about effectiveness of off-label use of recombinant factor VIIa.
Our review raises challenges for future research assessing hemostatic agents, particularly concerning the choice of outcomes. Blood loss and control of bleeding are difficult to record in a standardized manner. Transfusion protocols should be supplied. The presence of a protocol was shown to decrease the effect of an intervention, as measured by reduction in use of allogeneic blood, compared with studies that had no transfusion protocol. 39−41 In the studies included in our review, transfusion protocols were not always provided, and even less frequently were protocols reported for hemostatically active co-interventions such as plasma and platelet products (Tables 1  and 2 ). Mortality is the key outcome for therapeutic trials. However, in our review, we found that the baseline risk of death in the control groups ranged from 0% to 30%, with a mean of 20%. If we assumed a baseline risk of 20% and designed a superiority trial with an α level of 0.05 and β level of 0.20 and an expected RR of 0.90 (equivalent to a mortality of 18% in the treatment group), the trial would require about 12 000 patients to detect this difference. The cumulative number of participants evaluated to date in therapeutic trials is less than a quarter of this number.
Limitations
We were not able to obtain additional outcome data from some studies to allow them to be included in the pooled analyses. These studies generally showed no difference between recombinant factor VIIa and placebo; therefore, their inclusion might be expected to move values further toward a no-difference summary estimate. In addition, we included only published full-text articles. Although publication bias was investigated and has been previously explored, 7 it is impossible to completely exclude it.
Conclusion
Clinically significant benefits of recombinant factor VIIa as a general hemostatic agent in patients without hemophilia remain unproven. Our systematic review did not show a consistent benefit of off-label use of recombinant factor VIIa in the therapeutic setting and at best only modest benefits in the prophylactic setting. Given its potential risks, off-label use of this hemostatic agent cannot be recommended, and in most instances, it should be restricted to clinical trials. 
